MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Merus NV

Cerrado

SectorSalud

94.33

Resumen

Variación precio

24h

Actual

Mínimo

94

Máximo

94.44

Métricas clave

By Trading Economics

Ingresos

-62M

-158M

Ventas

-18M

8.8M

Margen de beneficio

-1,792.229

Empleados

260

EBITDA

-18M

-111M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+3.52% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.2B

7.1B

Apertura anterior

94.33

Cierre anterior

94.33

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

90 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Merus NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 oct 2025, 20:45 UTC

Ganancias

Costco Wholesale Sales Climb in September, Early October

8 oct 2025, 20:12 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 oct 2025, 16:39 UTC

Principales Movimientos del Mercado

Mining Shares Rise as Gold Prices Soar

8 oct 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

8 oct 2025, 23:43 UTC

Charlas de Mercado

Gold Falls on Possible Profit-Taking -- Market Talk

8 oct 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

JD Logistics to Finance Acquisition Using Internal Funds

8 oct 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 oct 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 oct 2025, 21:54 UTC

Charlas de Mercado
Ganancias

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 oct 2025, 21:30 UTC

Charlas de Mercado

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 oct 2025, 21:26 UTC

Charlas de Mercado
Ganancias

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 oct 2025, 19:15 UTC

Charlas de Mercado

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 oct 2025, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 oct 2025, 18:47 UTC

Charlas de Mercado

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

TaskUs Will Remain a Publicly Traded Co >TASK

8 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 oct 2025, 18:07 UTC

Charlas de Mercado

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 oct 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

8 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 oct 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 oct 2025, 15:57 UTC

Charlas de Mercado

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 oct 2025, 15:56 UTC

Charlas de Mercado

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 oct 2025, 15:53 UTC

Charlas de Mercado

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 oct 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 oct 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 oct 2025, 15:43 UTC

Adquisiciones, fusiones, absorciones

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 oct 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparación entre iguales

Cambio de precio

Merus NV Esperado

Precio Objetivo

By TipRanks

3.52% repunte

Estimación a 12 meses

Media 97.71 USD  3.52%

Máximo 112 USD

Mínimo 92 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merus NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

17 ratings

4

Comprar

13

Mantener

0

Vender

Puntuación técnica

By Trading Central

39.445 / 44.36Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

90 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
help-icon Live chat